
Hologic (HOLX) Stock Forecast & Price Target
Hologic (HOLX) Analyst Ratings
Bulls say
Hologic is positioned for positive growth due to anticipated organic revenue growth of 5-7%, driven by strong procedure volume increases, new product launches, and strategic tuck-in acquisitions across its Diagnostics, Breast Health, and GYN Surgical segments. The company’s bull case scenario projects revenue growth potentially accelerating to the high single digits (7-9%), supported by improvements in operating margins and a robust balance sheet with limited leverage. Additionally, expected operational efficiencies could deliver 8-12% earnings growth, further enhancing the overall financial outlook as business trends exhibit increasing favorability.
Bears say
Hologic faces a negative outlook primarily due to projected revenue growth slowing to low-single digits, attributed to weaknesses in both the Diagnostics and Breast Health segments, which are critical to its business model. The company has experienced disappointing returns over the past three and five years, with recent trends suggesting that anticipated growth in revenue and operational margins may not materialize, particularly amidst sluggish demand in Breast Health. Additional risks include potential market share loss, challenges related to integration from recent acquisitions, and a broader economic downturn that could further depress demand across its product offerings.
This aggregate rating is based on analysts' research of Hologic and is not a guaranteed prediction by Public.com or investment advice.
Hologic (HOLX) Analyst Forecast & Price Prediction
Start investing in Hologic (HOLX)
Order type
Buy in
Order amount
Est. shares
0 shares